Remote Multichannel Monitoring of Patients With Chronic DIseAses Using Speech technoLogies Based On Artificial intelliGence
Launched by I.M. SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY · Oct 15, 2024
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The DIALOG study is looking at how well a new remote monitoring system works for patients with chronic diseases like heart failure, diabetes, and high blood pressure after they leave the hospital. This system uses voice technology and smart data analysis to help doctors quickly spot any early problems or worsening health conditions, allowing for timely intervention.
To participate, you need to be between the ages of 65 and 74 and have a diagnosed chronic condition that is stable at the time of your hospital discharge. You will also need to be able to use devices like a blood pressure monitor or glucose meter at home. If you decide to join the study, you will get support through this remote system, which aims to keep you healthy and prevent complications. However, this study is not for everyone—it excludes those with severe cognitive challenges or those who have difficulty following instructions due to other health issues. The study is not yet recruiting participants, but it aims to help improve care for patients with chronic diseases in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Disease diagnosed according to the latest Clinical practice guidelines
- • Stable condition at the time of discharge from the hospital
- • Written informed consent to participate in the study
- Non-inclusion criteria:
- • Diagnosed dementia or severe cognitive impairment
- • The inability to use automatic devices to register blood pressure at home, a blood glucose meter
- • Alcohol or drug abuse
- • Inability to contact a voice assistant and other study requirements, due to major co-morbidities, social or financial issues, or a history of noncompliance with medical regimens, that might compromise the patient's ability to understand and/or comply with the protocol instructions or follow-up procedures
- Exclusion Criteria:
- • Unwillingness of the patient to continue participating in the study
- • The development of conditions related to the criteria of non-inclusion
About I.M. Sechenov First Moscow State Medical University
i.m. Sechenov First Moscow State Medical University is a prestigious institution dedicated to advancing medical education, research, and clinical practice. As a leading center for medical innovation in Russia, the university fosters a collaborative environment for scientific inquiry and the development of novel therapies. With a commitment to high-quality clinical trials, i.m. Sechenov aims to contribute significantly to the global biomedical landscape by evaluating new treatments and improving patient care through rigorous research methodologies and ethical standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Moscow, , Russian Federation
Patients applied
Trial Officials
Maria Kozhevnikova, Professor
Principal Investigator
The Sechenov First Moscow State Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported